deferoxamine has been researched along with Cholera Infantum in 9 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conclude that the short-term use of L1, with or without DFO, was safe and efficacious in our Chinese patient cohort." | 2.72 | A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. ( Chan, GC; Chik, KW; Ha, SY; Lam, CW; Lee, AC; Ling, SC; Luk, CW; Ng, IO, 2006) |
| " Chelation therapy with desferrioxamine mesylate did not cause adverse effects in any of the dogs and all survived to discharge." | 1.35 | Acute toxicity in five dogs after ingestion of a commercial snail and slug bait containing iron EDTA. ( Davis, RM; Haldane, SL, 2009) |
| " When administered to rodents at a daily dosage of 384 mumol/kg over a period of 10 days, drug 1 demonstrated severe renal toxicity." | 1.29 | A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. ( Bergeron, RJ; Creary, EA; Daniels, RD; King, W; Luchetta, G; Moerker, T; Peter, HH; Streiff, RR; Wiegand, J, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (22.22) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haldane, SL | 1 |
| Davis, RM | 1 |
| Wood, DM | 1 |
| Thomson, AH | 1 |
| Lawes, M | 1 |
| Jones, AL | 1 |
| Dargan, PI | 1 |
| Piga, A | 1 |
| Roggero, S | 1 |
| Vinciguerra, T | 1 |
| Sacchetti, L | 1 |
| Gallo, V | 1 |
| Longo, F | 1 |
| Ha, SY | 1 |
| Chik, KW | 1 |
| Ling, SC | 1 |
| Lee, AC | 1 |
| Luk, CW | 1 |
| Lam, CW | 1 |
| Ng, IO | 1 |
| Chan, GC | 1 |
| Tanner, MA | 1 |
| Galanello, R | 1 |
| Dessi, C | 1 |
| Smith, GC | 1 |
| Westwood, MA | 1 |
| Agus, A | 1 |
| Roughton, M | 1 |
| Assomull, R | 1 |
| Nair, SV | 1 |
| Walker, JM | 1 |
| Pennell, DJ | 1 |
| Babos, M | 1 |
| Schwarcz, A | 1 |
| Randhawa, MS | 1 |
| Marton, B | 1 |
| Kardos, L | 1 |
| Palkó, A | 1 |
| Henretig, FM | 2 |
| Temple, AR | 2 |
| Bergeron, RJ | 1 |
| Streiff, RR | 1 |
| Creary, EA | 1 |
| Daniels, RD | 1 |
| King, W | 1 |
| Luchetta, G | 1 |
| Wiegand, J | 1 |
| Moerker, T | 1 |
| Peter, HH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for deferoxamine and Cholera Infantum
| Article | Year |
|---|---|
Deferiprone: New insight.
Topics: Agranulocytosis; Cardiomyopathies; Clinical Trials as Topic; Deferiprone; Deferoxamine; Follow-Up St | 2005 |
2 trials available for deferoxamine and Cholera Infantum
| Article | Year |
|---|---|
A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong.
Topics: Adolescent; Adult; Arthralgia; beta-Thalassemia; Biopsy, Needle; Chelation Therapy; Child; Combined | 2006 |
A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
Topics: Adult; Agranulocytosis; Arthralgia; beta-Thalassemia; Chelation Therapy; Deferiprone; Deferoxamine; | 2007 |
6 other studies available for deferoxamine and Cholera Infantum
| Article | Year |
|---|---|
Acute toxicity in five dogs after ingestion of a commercial snail and slug bait containing iron EDTA.
Topics: Animals; Deferoxamine; Dog Diseases; Dogs; Female; Gastrointestinal Diseases; Iron; Male; Siderophor | 2009 |
Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child.
Topics: Anemia, Iron-Deficiency; Chemical and Drug Induced Liver Injury; Child, Preschool; Deferoxamine; Fer | 2005 |
In vitro evaluation of alternative oral contrast agents for MRI of the gastrointestinal tract.
Topics: Administration, Oral; Cacao; Contrast Media; Deferoxamine; Gadolinium DTPA; Gastrointestinal Disease | 2008 |
Acute iron poisoning in children.
Topics: Cardiovascular Diseases; Cathartics; Central Nervous System Diseases; Chemical and Drug Induced Live | 1984 |
Acute iron poisoning in children.
Topics: Acute Disease; Animals; Cardiovascular Diseases; Central Nervous System Diseases; Child; Child, Pres | 1984 |
A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Topics: Animals; Cebus; Deferoxamine; Dihydropyridines; Feces; Gastrointestinal Diseases; Iron; Kidney Disea | 1993 |